Drug Discovery World

FEBRUARY 28, 2024

A Phase I clinical trial, sponsored and managed by Cancer Research UK’s Centre for Drug Development, tested whether a type of antibody called IgE could be used to treat cancer. The drug, MOv18 IgE (an anti-folate receptor alpha IgE antibody), was developed by researchers at King’s College London.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

DrugBank

AUGUST 15, 2024

Drug development is challenging, including not only the complexities of biomolecular drug mechanisms but also the convolutions of regulatory pathways and commercialization strategies. This includes funding large-scale clinical trials and establishing robust manufacturing/distribution networks.

Drug Development 82

Drug Development Clinical Trials Drugs Therapies 82

Drug Discovery World

JUNE 19, 2023

Anoat Therapeutics’ goal is to bring a transformative and mutation-agnostic treatment option to CF patients for whom existing therapies are not effective – for example, patients not eligible or responsive to CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator therapies.

Therapies 130

Therapies Science Regulations Treatment 130

Drug Discovery World

AUGUST 4, 2023

Sven identified the two most prominent barriers as financing, and how to get ground-breaking therapies to the patients that most need them around the world. Sven identified the two most prominent barriers as financing, and how to get ground-breaking therapies to the patients that most need them around the world.

Therapies 130

Therapies Pharma Companies Marketing Treatment 130

Drug Discovery World

JULY 5, 2023

Join DDW for this exclusive free event , A Comprehensive Guide to Using Adeno-Associated Virus (AAV) Vectors in Gene Therapy, which is supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers.

Virus 130

Virus Therapies Bioinformatics Packaging 130

Drug Discovery World

JUNE 29, 2023

Join DDW for this exclusive free event , A Comprehensive Guide to Using Adeno-Associated Virus (AAV) Vectors in Gene Therapy, which is supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers.

Virus 130

Virus Therapies Bioinformatics Packaging 130

Drug Discovery World

JUNE 22, 2023

Join DDW for this exclusive free event , A Comprehensive Guide to Using Adeno-Associated Virus (AAV) Vectors in Gene Therapy, which is supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers.

Virus 130

Virus Therapies Bioinformatics Packaging 130

Drug Discovery World

MARCH 6, 2023

The post Institiute gives a boost to five new life science start-ups appeared first on Drug Discovery World (DDW). In total, BII’s start-ups have raised over €333 million in external funding from both local and international investors.

Science 130

Science RNA Disease International 130

Drug Target Review

AUGUST 7, 2024

The pharmaceutical industry is undergoing a major shift towards the development of breakthrough medicines and advanced therapies. This continued innovation highlights the complexity of the drug development process, particularly as the field is highly regulated by health authorities around the world.

Drug Development 59

Drug Development Clinical Pharmacology Clinical Trials Packaging 59

Alta Sciences

JULY 25, 2024

Top 10 Life Science Resources for Summer 2024 pmjackson Thu, 07/25/2024 - 14:44 There’s a lot of life science content out there, which is why we’ve curated a selection of our expert insights, tips, case studies, and scientific and regulatory information for your convenience. Tags Science and Health Weight 16 Read the eBook.

Science 52

Science Clinical Trials Clinical Pharmacology FDA 52

Drug Discovery World

SEPTEMBER 6, 2022

In recent years the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are not only transforming the way diseases are treated but are also aiming to cure entirely new patient populations. Record breaking investments in 2021 fuel an industry on fire . billion raised.

Therapies 130

Therapies Clinical Trials Production Disease 130

Drug Discovery World

FEBRUARY 27, 2023

For founders planning to launch their start-ups, specifically drug developers, there needs to be sound, foundational science with promising data that will enable you to push further down the drug discovery pipeline. DS: You were recognised in the 2023 Forbes’ 30 under 30 for Science.

RNA 130

RNA Science Small Molecule Engineering 130

Drug Discovery World

SEPTEMBER 6, 2022

Tony Khoury, Executive Vice President of Project Farma and Anshul Mangal , President & General Counsel of Project Farma, share how the industry is leveraging stronger education programmes to close the advanced therapy talent gap. . The need for solutions to the industry’s biggest bottlenecks are growing daily. .

Therapies 130

Therapies Clinical Trials Government Production 130

Drug Target Review

AUGUST 9, 2024

The science behind drug formulation The formulation of a drug is both an art and a science, requiring a deep understanding of the drug’s chemical and physical properties. 1 Challenges in drug formulation Developing a successful drug formulation is fraught with challenges.

Science 59

Science Drugs Compliance Drug Development 59

Drug Discovery World

OCTOBER 21, 2022

While advances in treatment over the last few years have resulted in good overall survival rates for patients with non-metastatic disease (90% five-year survival rate in the US 1 ), outcomes are still poor in certain cancers that do not respond to standard therapies. 3D bioprinted breast cancer tumours.

Therapies 130

Therapies Small Molecule Immune Response Engineering 130

Alta Sciences

JUNE 11, 2024

My Attendance at the 2024 Boston Society Cell and Gene Therapy Conference pmjackson Tue, 06/11/2024 - 20:49 , via Wikimedia Commons" data-entity-type="file" data-entity-uuid="c7a7fa8b-b2fe-4d84-a75e-d1ba3a4e2caf" src="[link] width="742" height="249" loading="lazy" /> Ecm85, CC BY-SA 3.0

Therapies 52

Therapies Molecular Biology Immune Response Science 52

Alta Sciences

OCTOBER 30, 2023

Top 10 Life Science Resources pmjackson Mon, 10/30/2023 - 16:16 There’s a lot of life science content out there, which is why we’ve curated a selection of our expert insights, tips, case studies, and scientific and regulatory information for you. Catch up on what you may have missed below! The Altascientist : Issue No. Watch the video.

Science 52

Science Clinical Trials Pharmacokinetics Pharmacy 52

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. Historically, what has limited investor interest in funding neurological and psychiatric therapies in development?

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Drug Target Review

JANUARY 8, 2024

Contrary to popular belief, ageing is not caused by just random wear and tear of our bodies over time but is instead caused by a discrete set of biological mechanisms that we now better understand and can target with therapies. a clinical-stage private biopharma company developing therapies for neurological and psychiatric diseases.

Science 145

Science Disease FDA Approval Pharmaceutical Companies 145

Drug Discovery World

FEBRUARY 12, 2024

Cameron Ross, SVP, Generative AI, Elsevier “AI has the potential to dramatically shorten one of the most costly areas of early drug development – small molecule discovery. It’s no surprise that interest in AI for this area is surging, since early phase drug discovery normally accounts for 42% of the cost of the entire pipeline.

Small Molecule 349

Small Molecule Regulations Clinical Trials Therapies 349

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Discovery World

FEBRUARY 2, 2024

Dr Mummery (UCL Queen Square Institute of Neurology and UCLH consultant neurologist) said: “We are at a historic point in dementia research with disease-modifying therapies emerging.

Research 250

Research Clinical Trials Trials Science 250

Drug Discovery World

JULY 20, 2023

This is the latest episode of the free DDW narrated podcast, “A business case for drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. In the first article, Drug Discovery World Editor Reece Armstrong looks at how a number of deals in pharma have sparked excitement in the industry.

Drug Development 100

Drug Development Drugs Therapies Science 100

Drug Discovery World

OCTOBER 17, 2023

The DDW Turning Science into Business Summit, ‘ Cancer research opportunities and advances ’ will feature experts and thought leaders in cancer research, precision medicine and immunotherapy. The presentation will address important issues in antibody drug development, including choosing the right biomarker, drug formulation and manufacturing.

Marketing 130

Marketing Research Clinical Trials Science 130

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

FDA Law Blog: Drug Discovery

MAY 19, 2024

aimed at identifying and characterizing the challenges in developing therapies for ultra-rare diseases and conditions that affect exceedingly small populations. By Sarah Wicks — On May 21, 2024, the EveryLife Foundation for Rare Diseases (ELF) will host a Scientific Workshop at the National Press Club in Washington, D.C.

Disease 59

Disease Therapies Drug Development FDA 59

Drug Discovery World

JUNE 8, 2023

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this latest episode, DDW’s Megan Thomas is in conversation with Dr Pierre Eftehkari, Chief Sceitnific Officer of Inoviem Scientific.

Drug Development 130

Drug Development Science Pharmaceuticals Therapies 130

Drug Discovery World

APRIL 5, 2024

This has been a busy week in the field of neuroscience drug discovery, with EU approval for a long-acting schizophrenia treatment, research revealing new insights into autism, the formation of a partnership focused on ALS drug development and the launch of a new company targeting neurological disorders.

Drugs 130

Drugs Therapies Science Treatment 130

Drug Discovery World

FEBRUARY 5, 2024

The launches include an integrated solution suite for liquid biopsy workflows, and the Resolvex i300 and antibody purification columns AffinEx Protein A Capture, adding biomarker discovery, drug development and personalised medicine research to proteomics workflows.

Small Molecule 162

Small Molecule Assay Development Production Science 162

Drug Discovery World

MAY 6, 2024

Thanks to a prestigious academic legacy, Europe has long been a dominant region for life sciences. In this article, DDW’s Diana Spencer highlights several prominent hotspots that are taking the lead on advancing European drug discovery and development. This article takes a closer look at several key clusters in the region.

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

Perficient: Drug Development

SEPTEMBER 22, 2023

With a highly skilled team of Salesforce consultants and developers with Healthcare and Life Sciences (HLS) experience, Perficient is especially interested in this year’s announcements for the vertical. Here are takeaways for Salesforce clients, consultants, and developers working in HLS.

Science 59

Science Clinical Trials Engineering Production 59

SCIENMAG: Medicine & Health

JUNE 14, 2023

Although effective drugs and therapies have been developed for most breast cancer subtypes, triple negative breast cancer lacks the key receptors that these drugs interact with – in other words, it’s negative for the three receptors for which […]

Drug Development 87

Drug Development Drugs Therapies Science 87

Drug Discovery World

JUNE 8, 2023

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this latest episode, DDW’s Megan Thomas is in conversation with Dr Pierre Eftehkari, Chief Scientific Officer of Inoviem Scientific.

Drug Development 130

Drug Development Science Pharmaceuticals Therapies 130

Drug Discovery World

JULY 20, 2023

This is the latest episode of the free DDW narrated podcast, “A business case for drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. In the first article, Drug Discovery World Editor Reece Armstrong looks at how a number of deals in pharma have sparked excitement in the industry.

Drugs 100

Drugs Drug Development Therapies Science 100

Drug Discovery World

SEPTEMBER 26, 2023

Synthetic biology has shown significant potential to the drug discovery sector. Although not a new area of science, the prominence of this technology and its applications – evident during the Covid-19 pandemic – have increased of late. appeared first on Drug Discovery World (DDW).

Vaccine 130

Vaccine Drug Development Science Marketing 130

Drug Discovery World

JULY 3, 2024

As such it would be easy to dismiss the life sciences sector, an historical strong point in the UK, as a sector unimportant to the parties in this election, but this shouldn’t be the case. A recent report by the Medicines Discovery Catapult (MDC) really highlights the current challenges UK drug developers face by operating within the country.

Government 147

Government Drugs Science International 147

Drug Discovery World

SEPTEMBER 12, 2022

If anything, this period has been a reminder that people are the primary reason we do what we do, and the Patient Access, Healthcare & People track at Advanced Therapies Europe 2022 allowed DDW’s Multimedia Editor Megan Thomas to share several reflections on the topic. .

Clinical Trials 130

Clinical Trials Trials Therapies Science 130